Multiple Myeloma Treatment Shifts Earlier as Advanced Therapies Expand — Spherix Global Insights

Event summary

80% of physicians now view high-risk smoldering multiple myeloma (HR-SMM) as an earlier clinically actionable stage of MM.
59% of physicians report changing their approach to HR-SMM in the past year, including more frequent monitoring and earlier treatment.
68% of relapsed/refractory multiple myeloma (RRMM) patients had progressed or relapsed within the previous 12 months.
Nearly two-thirds of physicians are extremely comfortable using advanced therapies earlier in the treatment journey.

The big picture

The multiple myeloma treatment landscape is evolving on two fronts: earlier intervention in high-risk smoldering cases and expanded advanced therapy options for relapsed patients. This shift requires physicians to navigate complex treatment sequencing decisions, balancing immediate efficacy with long-term patient outcomes. The growing acceptance of HR-SMM as a treatable stage, coupled with increasing comfort with advanced therapies, suggests a market where differentiation will depend on demonstrating value across the entire treatment continuum.

What we're watching

Early Intervention Adoption: How the growing acceptance of HR-SMM as a treatable stage will impact future treatment algorithms and physician practices.
Advanced Therapy Sequencing: Whether physicians can effectively balance immediate treatment needs with long-term eligibility for advanced therapies in RRMM patients.
Pipeline Innovation: The pace at which emerging therapies like DETER-SMM and CAR-PRISM will enter the market and reshape treatment strategies.